

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS, INC., and MYLAN
PHARMACEUTICALS, INC.,
Petitioner,

v.

NOVARTIS AG and LTS LOHMANN THERAPIE-SYSTEME
AG,
Patent Owner.

IPR2014-00549 and IPR2014-00550
Patents 6,316,023 B1 and 6,335,031 B1

Held: June 2, 2015

BEFORE: FRANCISCO C. PRATS, ERICA A. FRANKLIN,
and CHRISTOPHER G. PAULRAJ, Administrative Patent
Judges.

The above-entitled matter came on for hearing on Tuesday, June
2, 2015, commencing at 1:00 p.m., at the U.S. Patent and
Trademark Office, 600 Dulany Street, Alexandria, Virginia.

IPR2014-00549 and IPR2014-00550
Patents 6,316,023 B1 and 6,335,031 B1

APPEARANCES:

ON BEHALF OF THE PETITIONER:

MICHAEL K. LEVY, ESQUIRE
CHRIS J. COULSON, ESQUIRE
Kenyon & Kenyon, LLP
One Broadway
New York, New York 10004-1007

BENJAMIN ANGER, ESQUIRE
Knobbe Martens
12790 El Camino Real
San Diego, California 92130

ON BEHALF OF PATENT OWNER:

CHARLOTTE JACOBSEN, ESQUIRE
RAYMOND R. MANDRA, ESQUIRE
NICHOLAS N. KALLAS, ESQUIRE
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, New York 10104-3800

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

P R O C E E D I N G S

- - - - -

JUDGE PRATS: Good afternoon, everyone. We are here for IPR2014-00549 and IPR2014-00550. This is the final hearing for those cases. Welcome everyone and thank you for coming.

These involve respectively, the 549 involves U.S. patent number 6,316,023 and the 550 involves patent number 6,335,031. The parties are -- Petitioner is Noven Pharmaceuticals and Patent Owner is Novartis and LTS Lohmann Therapie-Systeme.

I would like to point out that the 549 and 550 proceedings have been joined with IPR2015-00265 and 00268 respectively. The Petitioner in those proceedings is Mylan Pharmaceuticals. Mylan will not be presenting argument today.

At this time I would like counsel for the parties to introduce yourselves and your colleagues, beginning with Petitioner, Noven.

MR. LEVY: Good afternoon, Your Honors. Mike Levy from Kenyon & Kenyon on behalf of Petitioner, Noven.

MR. COULSON: I'm Chris Coulson also for Noven, Your Honors.

MS. JACOBSEN: Good afternoon, Your Honors. Charlotte Jacobsen on behalf of Novartis and LTS. And with me

1 is Nicholas Kallas and Raymond Mandra from the firm
2 Fitzpatrick Cella.

3 MR. ANGER: Your Honors, I'm Ben Anger
4 representing Mylan Pharmaceuticals, Inc.

5 MR. LEVY: And Your Honor, on behalf of Petitioners,
6 Steve Lee is also counsel of record and joining us as well.

7 JUDGE PRATS: Thank you. Welcome to the Board.
8 Consistent with our hearing order, each party has 60 minutes to
9 present their arguments. Petitioner you may reserve rebuttal time.

10 As to procedure, I note that Patent Owner has made
11 objections to a number of Petitioner's demonstrative slides.
12 When we present a particular slide, we are not going to interrupt
13 the opposition and say, well, I object to that slide. We are just
14 going to continue through argument. Is that clear?

15 Let me go through and make sure I haven't missed
16 anything. Okay. Counsel for Petitioner, you may proceed.
17 Would you like to reserve any rebuttal time?

18 MR. LEVY: Yes, Your Honors, I would like to reserve
19 20 minutes for rebuttal.

20 Good afternoon, Your Honors, and may it please the
21 Court. Again, Mike Levy for Petitioner. The main question
22 posed to the Board is whether a person of ordinary skill in the art
23 or a POSA would have expected that rivastigmine was
24 susceptible to oxidation, whether the prior art suggested the
25 existence of the problem.

1 There's no real dispute, or there shouldn't be, that the
2 solution to the problem, antioxidant use, is obvious. The
3 expectation of oxidative degradation provides the motivation to
4 take the otherwise unremarkable step of adding an antioxidant to
5 pharmaceutical compositions.

6 The Board is now aware of the Federal Circuit's recent
7 decision upholding a District Court's finding that other defendants
8 failed to prove obviousness by clear and convincing evidence
9 based on the record in that proceeding for the patents here. To be
10 sure, there is substantially more evidence here and different
11 evidence than that previous case, and it is particularly evidence
12 addressing the central issue of whether a POSA would have
13 suspected rivastigmine's susceptible to oxidation.

14 Petitioner provided expert testimony evidence from two
15 distinguished individuals. Dr. Christian Schöneich is the chair of
16 the department of pharmaceutical chemistry at the University of
17 Kansas. The focus of his professional work, his research since
18 the early 1990s has been free radical chemistry which includes
19 the very types of oxidation issues presenting in this case. He is
20 the only declarant in this case whose expertise is oxidation in
21 pharmaceutical chemistry.

22 And the other, Dr. Agis Kydonieus, is the president of
23 Samos Pharmaceuticals, a company serving the pharmaceutical
24 industry in the field of drug delivery. Dr. Kydonieus has spent
25 his entire professional career outside of academia in industry and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.